STML Stemline Therapeutics, Inc.

8.90
+0  (2%)
Previous Close 8.70
Open 8.80
Price To book 2.71
Market Cap 159.76M
Shares 17,951,000
Volume 149,619
Short Ratio 3.69
Av. Daily Volume 388,284

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 ongoing. ASH oral presentation - December 2016.
SL-401
High Risk Myeloproliferative Neoplasms
Phase 2 enrollment to be completed 1Q 2017. Data due 2H 2017.
SL-401
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) cancer
Phase 2 preliminary data released November 2016.
SL-701
Second line glioblastoma (GBM) cancer
Phase 2 ongoing. ASH oral presentation - December 2016.
SL-401
Cancer- adult relapsed or refractory acute myeloid leukemia (AML)

Latest News

  1. DEADLINE TOMORROW: Lundin Law PC Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Reminds Investors with Losses to Contact the Firm
  2. FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Stemline Therapeutics, Inc. (STML) and Lead Plaintiff Deadline: April 4, 2017
  3. DEADLINE TOMORROW: Levi & Korsinsky, LLP Reminds Shareholders it Filed a Complaint to Recover Losses Suffered by Investors in Stemline Therapeutics, Inc. - Lead Plaintiff Deadline of April 4, 2017 - STML
  4. STEMLINE 96 HOUR DEADLINE ALERT: APPROXIMATELY 96 HOURS REMAIN; FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS of Deadline in Class Action Lawsuit Against Stemline Therapeutics, Inc. – (STML)
  5. UPCOMING DEADLINE ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Reminds Investors with Losses to Contact the Firm
  6. STML UPCOMING DEADLINE: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Stemline Therapeutics, Inc. and a Lead Plaintiff Deadline of April 4, 2017
  7. DEADLINE TUESDAY: Lundin Law PC Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
  8. April 4 Deadline Alert: Law Offices of Howard G. Smith Reminds Stemline Therapeutics, Inc. Investors of Upcoming Lead Plaintiff Deadline
  9. APRIL 4 DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
  10. Deadline Alert: GPM Reminds Investors of the April 4 Deadline in the Class Action Lawsuit Against Stemline Therapeutics, Inc.
  11. DEADLINE APPROACHING: Lundin Law PC Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Reminds Investors with Losses to Contact the Firm
  12. DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Stemline Therapeutics, Inc. (STML) & Lead Plaintiff Deadline: April 4, 2017
  13. EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
  14. DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Stemline Therapeutics, Inc. To Contact The Firm
  15. SHAREHOLDER ALERT: Goldberg Law PC Announces the Filing of a Securities Class Action Lawsuit against Stemline Therapeutics, Inc.
  16. INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in Stemline Therapeutics, Inc.
  17. IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
  18. EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Stemline Therapeutics, Inc. - STML
  19. STEMLINE SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit against Stemline Therapeutics, Inc. – (STML)